Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PF-07284890 + PF-07799544 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07284890 | PF07284890|PF 07284890|ARRY-461|ARRY461|ARRY 461 | BRAF Inhibitor 25 | PF-07284890 inhibits BRAF, potentially leading to inhibition of tumor growth and tumor regression (Cancer Res 2021;81(13_Suppl):Abstract nr 1473). | |
PF-07799544 | PF 07799544|PF07799544|ARRY-134|ARRY 134|ARRY134 | MEK inhibitor (Pan) 26 | PF-07799544 is a brain-penetrant MEK inhibitor, which reduces downstream signaling and potentially decreases tumor cell proliferation (J Clin Oncol 42, 2024 (suppl 16; abstr 3154), NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05538130 | Phase I | PF-07799544 Encorafenib + PF-07799544 PF-07284890 + PF-07799544 PF-07799544 + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors | Recruiting | USA | CAN | 0 |